Want to see CCEL full AI Analyst Report?
CCEL Stock Chart & Stats
$4.09
-$0.37(-4.74%)
At close: 4:00 PM EST
$4.09
-$0.37(-4.74%)
Day’s Range― - ―
52-Week Range$2.72 - $5.43
Previous CloseN/A
Volume3.40K
Average Volume (3M)4.07K
Market Cap
$27.66M
Enterprise Value$30.58M
Total Cash (Recent Filing)$2.90M
Total Debt (Recent Filing)$2.40M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Jul 09, 2026Next Dividend Ex-DateN/A
Dividend Yield11.14%
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,055,150
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda51.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.11
Revenue Forecast (FY)$30.30M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsMid-70% gross margins indicate durable unit economics for Cryo-Cell's processing and storage services. High gross margins provide structural room to cover SG&A and invest in customer acquisition or facility upkeep, supporting margin resilience even if top-line growth is slow.
Positive Operating And Free Cash FlowConsistent positive operating cash flow and recent positive free cash flow show the business converts recurring storage fees into cash despite reported accounting losses. This cash generation reduces near-term refinancing risk and supports ongoing operations and regulatory remediation efforts.
Lowered Debt LevelsMeaningful debt reduction improves financial flexibility and reduces interest burden, which enhances the company's ability to execute a turnaround plan. Lower leverage also increases runway for operating cash flow to stabilize results without immediate refinancing or aggressive cost cutting.
Bears Say
Persistent Stockholders' DeficitA persistent negative equity position materially weakens financial flexibility and heightens solvency concerns. It limits access to capital markets, can trigger covenant or listing issues, and raises the likelihood management must pursue dilutive financing or asset sales to restore balance-sheet health.
Flat-to-declining RevenueStagnant or falling revenue undermines growth leverage for a subscription-style biobanking model; without net new enrollments or improved retention, fixed-cost absorption worsens and margin advantages may erode, making long-term profitability recovery more difficult.
NYSE Compliance OverhangRegulatory monitoring and a formal remediation timetable impose execution risk and public scrutiny. Failure to meet milestones could lead to delisting, pressuring management toward short-term fixes, possible dilutive capital raises, or asset dispositions that can impair long-term strategic flexibility.
Cryo-Cell International News
CCEL FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $2.72 and its highest was $5.43 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is $27.66M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Jul 09, 2026 which is yesterday.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Apr 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.03.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 11.14%. See more information on Cryo-Cell International Inc dividends here
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,055,150 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went up 1.09%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in CCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
CCEL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
―
DocGo
―
P3 Health Partners
―
Ownership Overview
35.79% Insiders
2.57% Mutual Funds
2.05% Other Institutional Investors
57.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---